KRYS icon

Krystal Biotech

132.18 USD
-4.99
3.64%
At close May 9, 4:00 PM EDT
After hours
132.18
+0.00
0.00%
1 day
-3.64%
5 days
-20.66%
1 month
-21.40%
3 months
-14.46%
6 months
-32.52%
Year to date
-15.54%
1 year
-16.73%
5 years
120.30%
10 years
1,142.29%
 

About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Employees: 275

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

72% more call options, than puts

Call options by funds: $63.3M | Put options by funds: $36.8M

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

2% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 96

1.04% less ownership

Funds ownership: 97.58% [Q3] → 96.55% (-1.04%) [Q4]

6% less funds holding

Funds holding: 279 [Q3] → 262 (-17) [Q4]

15% less capital invested

Capital invested by funds: $5.1B [Q3] → $4.35B (-$753M) [Q4]

24% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 50

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$189
43%
upside
Avg. target
$221
67%
upside
High target
$245
85%
upside

6 analyst ratings

positive
83%
neutral
17%
negative
0%
Guggenheim
Debjit Chattopadhyay
30% 1-year accuracy
8 / 27 met price target
43%upside
$189
Buy
Maintained
7 May 2025
Chardan Capital
Geulah Livshits
12% 1-year accuracy
8 / 68 met price target
66%upside
$219
Buy
Maintained
7 May 2025
HC Wainwright & Co.
Joseph Pantginis
18% 1-year accuracy
70 / 396 met price target
82%upside
$240
Buy
Reiterated
6 May 2025
Jefferies
Roger Song
28% 1-year accuracy
5 / 18 met price target
85%upside
$245
Buy
Initiated
5 Mar 2025
Citigroup
Yigal Nochomovitz
11% 1-year accuracy
4 / 36 met price target
63%upside
$215
Neutral
Maintained
20 Feb 2025

Financial journalist opinion

Based on 7 articles about KRYS published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
Neutral
Seeking Alpha
5 days ago
Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Stephane Paquette - VP, Corporate Development Krish Krishnan - Chairman and CEO Suma Krishnan - President, Research and Development Jennifer McDonough - SVP, Patient Access, Analytics and Operations Christine Wilson - SVP and Head, U.S. Sales and Marketing Kate Romano - CAO Conference Call Participants Alec Stranahan - Bank of America Roger Song - Jefferies Ritu Baral - TD Cowen Gavin Clark-Gartner - Evercore ISI Sami Corwin - William Blair Andrea Newkirk - Goldman Sachs Debjit Chattopadhyay - Guggenheim Securities Yigal Nochomovitz - Citigroup Operator Thank you for standing by, and welcome to the Krystal Biotech First Quarter 2025 Earnings Call. At this time, all participants are on a listen-only mode.
Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
5 days ago
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
Negative
Zacks Investment Research
5 days ago
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.20 per share, missing the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $0.03 per share a year ago.
Krystal Biotech, Inc. (KRYS) Misses Q1 Earnings and Revenue Estimates
Neutral
Zacks Investment Research
1 week ago
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Neutral
GlobeNewsWire
1 week ago
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing.
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Neutral
GlobeNewsWire
2 weeks ago
Krystal Biotech to Present at Upcoming Scientific Conferences
PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June.
Krystal Biotech to Present at Upcoming Scientific Conferences
Neutral
GlobeNewsWire
1 month ago
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth has also served as a valuable contributor on Jeune's board of directors since February 2021.
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Neutral
Zacks Investment Research
1 month ago
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Positive
Seeking Alpha
1 month ago
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, reimbursement issues, competition from Abeona's EB-101, and high operational expenses, which could impact short-term valuation and cash flow.
Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK
Charts implemented using Lightweight Charts™